<DOC>
	<DOCNO>NCT00772785</DOCNO>
	<brief_summary>Buprenorphine ( BPN ) approve treatment opioid dependence ; however , take oral tablet , patient experience withdrawal craving variable BPN level blood low . Probuphine ( buprenorphine implant ) implant place beneath skin contain BPN . It design provide 6 month stable BPN blood level . This study test safety efficacy Probuphine treatment patient opioid dependence . Patients complete least 24 week treatment Open-Label , Multi-Center Study Probuphine Patients Opioid Dependence ( PRO-807 Study ) , re-treated Probuphine additional 24 week .</brief_summary>
	<brief_title>Study Probuphine Patients With Opioid Dependence</brief_title>
	<detailed_description>This 6-month , open-label , multi-center extension study . It estimate approximately 200 patient enrol approximately 25 site United States ( US ) . Following completion either PRO-807 ( NCT00630201 ) PRO-808 study , eligible patient implanted Probuphine implant opposite arm PRO-809 study . Safety , BPN plasma level , efficacy measure collect 24-week treatment period .</detailed_description>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<criteria>Patients must meet following eligibility criterion : Expected complete 24 week treatment PRO807 PRO808 Voluntarily provide write informed consent prior conduct studyrelated procedure Deemed appropriate entry retreatment study Investigator Females childbearing potential fertile male must use reliable mean contraception Patients eligible enrollment follow criterion meet : Presence aspartate aminotransferase ( AST ) level ≥ 3 X upper limit normal and/or alanine aminotransferase ( ALT ) level ≥ 3 X upper limit normal and/or total bilirubin ≥ 1.5 X upper limit normal and/or creatinine ≥ 1.5 X upper limit normal , measured time Week 20 Visit previous trial ( PRO807 PRO808 ) , time le 5 week prior Implant Visit . Current diagnosis chronic pain require opioids treatment Pregnant lactating female Current use agent metabolize cytochrome P450 3A4 ( CYP 3A4 ) azole antifungal ( e.g. , ketoconazole ) , macrolide antibiotic ( e.g. , erythromycin ) , protease inhibitor ( e.g. , ritonavir , indinavir , saquinavir ) Current history coagulopathy anticoagulant therapy ( warfarin ) Current use benzodiazepine physician prescribe use Significant medical psychiatric symptom , cognitive impairment , factor opinion Investigator , would preclude compliance protocol , patient safety , adequate cooperation study , obtain informed consent Concurrent medical condition ( severe respiratory insufficiency ) may prevent patient safely participate study ; and/or pending legal action could prohibit participation and/or compliance study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>opioid dependence</keyword>
	<keyword>opioid addiction</keyword>
	<keyword>buprenorphine</keyword>
	<keyword>methadone</keyword>
	<keyword>heroin</keyword>
	<keyword>implant</keyword>
	<keyword>opioid withdrawal</keyword>
	<keyword>opioid pain medication</keyword>
	<keyword>suboxone</keyword>
</DOC>